Monocyte HLA-Dr Expression to Monitor Immune Response and Potential Infection Risks Following Vaso-Occlusive Crises in Patients with Sickle Cell Anemia Monocyte HLA-DR expression in SCA patients

Main Article Content

Romain Fort
Guillaume Monneret
Elie Nader
Giovanna Cannas
Philippe Connes
Fabienne Venet
Arnaud Hot


Sickle cell anemia, vaso-occlusive crisis, infection, HLA-DR expression, immune response, prognosis


No abstract required for a scientific letter


Download data is not yet available.
Abstract 113 | PDF Downloads 130 HTML Downloads 91


1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong KR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.

2. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: A review. International Journal of Infectious Diseases. 2010;14:e2–e12.

3. Ramakrishnan M, Moïsi JC, Klugman KP, Iglesias JM, Grant LR, Mpouti-Etame M, Levine OS. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:329–337.

4. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–1048.

5. McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J. Pediatr. 2011;158:505–507.

6. Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br. J. Haematol.2014;166:165–176.

7. Gavriilaki E, Mainou M, Christodoulou I, Koravou EE, Paleta A, Touloumenidou T, Papalexandri A, Athanasiadou A, Apostolou C, Klonizakis P, Anagnostopoulos A, Vlachaki E. In vitro evidence of complement activation in patients with sickle cell disease. Haematologica. 2017;102:e481–e482.

8. Prasad AS, Beck FW, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, Swerdlow P. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am. J. Hematol. 1999;61:194–202.

9. Wu JF, Ma J, Chen J, Ou-Yang B, Chen MY, Li LF, Liu YJ, Lin AH, Guan XD. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis. Crit Care. 2011;15:R220.

10. Gouel-Chéron A, Allaouchiche B, Guignant C, Davin F, Flocard B, Monneret G, for the AzuRea Group. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS ONE. 2012;7:e33095.

11. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med.2006;32:1175–1183.

12. Okpala I. The intriguing contribution of white blood cells to sickle cell disease - a red cell disorder. Blood Rev.2004;18:65–73.

13. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am. J. Hematol.2004;77:323–328.

14. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96:2451–2459.

15. Winkler MS, Rissiek A, Priefler M, Schwedhelm E, Robbe L, Bauer A, Zahrte C, Zoellner C, Kluge S, Nierhaus A. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression? PLoS ONE. 2017;12:e0182427.

16. Monneret G, Venet F. Monocyte HLA-DR in sepsis: shall we stop following the flow? Crit Care. 2014;18:102.

17. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92:2551–2555.

18. Keikhaei B, Mohseni AR, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F, Solgi G. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur. Cytokine Netw.2013;24:45–52.

19. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med.2001;163:316–321.

20. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, Vanhems P, Monneret G. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive CareMed. 2010;36:1859–1866.